Latest Breaking News On - Ibrutinib imbruvica - Page 1 : vimarsana.com

The IRA: Reducing Inflation Or Threatening Patient Access?

Observational Study Shows Frontline Ibrutinib With/Without Rituximab Is Safe and Effective in Low-Risk Mantle Cell Lymphoma

Ibrutinib with or without rituximab was effective and tolerable in patients with previously untreated, low-risk mantle cell lymphoma.

Dr Moustafa on Standard Treatment Approaches in MCL

Muhamad Alhaj Moustafa, MD, MS, discusses standard treatments for transplant-eligible and transplant-ineligible patients with mantle cell lymphoma.

Medicare Sends Initial Price Negotiation Bids to Drugmakers

Manufacturers of 10 drugs have 30 days to accept or make a counter-offer

Americans Often Pay 3 Times More for Medicare Drugs Up for Negotiation Than Comparable Countries

Based on a comparison of prices for drugs up for Medicare price negotiations, there is a long way to go to reach the prices of 7 comparable countries.

'Unequivocal' data emerges from trial of CLL therapy guided by minimal residual disease

Here's What You Need to Know About the Medicare Drug Price Negotiation Program

Maddocks Shares Updates on Emerging Treatment Strategies in MCL

Efforts to widen the treatment armamentarium for patients with mantle cell lymphoma have been thwarted by increased toxicities and resistance mechanisms with effective therapies such as BTK inhibitors.

Dr Kahl on the Potential for Frontline BTK Inhibitors in Mantle Cell Lymphoma

Brad S. Kahl, MD, discusses the potential for BTK inhibitors to shift the frontline treatment setting in mantle cell lymphoma.

Stelara and Enbrel Chosen for IRA Price Negotiation

The Biden administration has released the first 10 drugs subject to price negotiation with Medicare under the Inflation Reduction Act (IRA), and among those chosen were Stelara (ustekinumab) and Enbrel (etanercept), both of which will face biosimilar competition within the next decade.